Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa1467
Youjin Chang, J. Moon, Young Seok Lee, J. Shim
{"title":"The outcome of anticoagulation alone therapy for patients with submassive pulmonary embolism","authors":"Youjin Chang, J. Moon, Young Seok Lee, J. Shim","doi":"10.1183/13993003.congress-2019.pa1467","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa1467","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":"40 4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90272506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-22DOI: 10.1183/13993003.CONGRESS-2019.PA1468
Y. Havlucu, D. Kızılırmak
Background: The Khorana risk score (KRS)is the validated risk assessment model to stratify risks of venous thromboembolism (VTE) development in ambulatory patients with cancer. At this study we want to assess the predictive performance of KRS in patients with lung cancer. Methods: VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risks models. Results: We retrospectively analyzed patients with diagnosis of lung cancer at our clinic over ten years.912 patients with lung cancer were included study.98 patient were excluded from study due to various reasons. Among 814 patients with lung cancer,79(9,7%) cases of VTE were identified, including 61 (77,2%)pulmonary embolism,15 (19%)peripheral deep vein thrombosis, and 3(3,8%) thrombosis of other sites.A high KRS (cumulative incidence, 10,7%; 95% confidence interval [CI], 4,9-18,1%) was not associated with venous thromboembolism compared with an intermediate score(cumulative incidence, 9,8%; 95% confidence interval, 7,3-15,2%) in both univariate and multivariable analyses. Conclusions: By using khorona risk score, risk stratification (intermediate or high risk) of venous thromboembolism was not useful in patients with lung cancer.
{"title":"Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Lung Cancer","authors":"Y. Havlucu, D. Kızılırmak","doi":"10.1183/13993003.CONGRESS-2019.PA1468","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2019.PA1468","url":null,"abstract":"Background: The Khorana risk score (KRS)is the validated risk assessment model to stratify risks of venous thromboembolism (VTE) development in ambulatory patients with cancer. At this study we want to assess the predictive performance of KRS in patients with lung cancer. Methods: VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risks models. Results: We retrospectively analyzed patients with diagnosis of lung cancer at our clinic over ten years.912 patients with lung cancer were included study.98 patient were excluded from study due to various reasons. Among 814 patients with lung cancer,79(9,7%) cases of VTE were identified, including 61 (77,2%)pulmonary embolism,15 (19%)peripheral deep vein thrombosis, and 3(3,8%) thrombosis of other sites.A high KRS (cumulative incidence, 10,7%; 95% confidence interval [CI], 4,9-18,1%) was not associated with venous thromboembolism compared with an intermediate score(cumulative incidence, 9,8%; 95% confidence interval, 7,3-15,2%) in both univariate and multivariable analyses. Conclusions: By using khorona risk score, risk stratification (intermediate or high risk) of venous thromboembolism was not useful in patients with lung cancer.","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83299723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA3117
L. Shaaban, M. Othman, H. Abozaid, N. D. Mohamed
Background:Pulmonary embolism (PE) is the third most common acute cardiovascular disease after myocardial infarction and stroke and results in thousands of deaths each year because it often goes undetected. This study, aime to evaluate the role of non–contrast MSCT in detection of pulmonary embolism. Methods: One hundered patients requested for CT pulmonary angiography (pulmonary CTA) clinically evaluated according to revised Geneva scoring system undergone non-contrast and contrast-enhanced CT images of the chest and were reviewed separately. The average CT attenuation differences between the high attenuation clots and pulmonary arteries were computed. Findings in the non-contrast images were correlated with the contrast-enhanced images. Results: Twenty-six of 100 patients were positive for PE in CTAs. Mean age (± SD) was 56.73 (± 9.11) years, 17 (65.4%) were females, Geneva scoring revealed low, intermediate, high propablity(2%, 7%, and 17%) respectively. Of these 26 patients, 13 were positive for the hyperdense lumen sign in the non-contrast CT images with high, intermediate and low revised Geneva score 10(76%), 3 (23%), 0 (0%) respectively. The hyperdense lumen sign has an over-all sensitivity of 50 %, specificity of 98.6%. The other 13 patients; ten of them had more than one indirect sign. The most common indirect sign revealed high specificity 91% and statistical significant is the peripheral wedged shaped opacities. Conclusion: Non-contrast chest CT scans have good role in evaluation of PE through detection the hyperdense lumen sign that is a good indicator of acute pulmonary thromboembolism particularly in cases involving the central pulmonary arteries or peripheral wedge shaped opacity as useful indirect sign.
{"title":"Non-Contrast Chest CT Scans In Detection Of Pulmonary Thromboembolism","authors":"L. Shaaban, M. Othman, H. Abozaid, N. D. Mohamed","doi":"10.1183/13993003.CONGRESS-2018.PA3117","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3117","url":null,"abstract":"Background:Pulmonary embolism (PE) is the third most common acute cardiovascular disease after myocardial infarction and stroke and results in thousands of deaths each year because it often goes undetected. This study, aime to evaluate the role of non–contrast MSCT in detection of pulmonary embolism. Methods: One hundered patients requested for CT pulmonary angiography (pulmonary CTA) clinically evaluated according to revised Geneva scoring system undergone non-contrast and contrast-enhanced CT images of the chest and were reviewed separately. The average CT attenuation differences between the high attenuation clots and pulmonary arteries were computed. Findings in the non-contrast images were correlated with the contrast-enhanced images. Results: Twenty-six of 100 patients were positive for PE in CTAs. Mean age (± SD) was 56.73 (± 9.11) years, 17 (65.4%) were females, Geneva scoring revealed low, intermediate, high propablity(2%, 7%, and 17%) respectively. Of these 26 patients, 13 were positive for the hyperdense lumen sign in the non-contrast CT images with high, intermediate and low revised Geneva score 10(76%), 3 (23%), 0 (0%) respectively. The hyperdense lumen sign has an over-all sensitivity of 50 %, specificity of 98.6%. The other 13 patients; ten of them had more than one indirect sign. The most common indirect sign revealed high specificity 91% and statistical significant is the peripheral wedged shaped opacities. Conclusion: Non-contrast chest CT scans have good role in evaluation of PE through detection the hyperdense lumen sign that is a good indicator of acute pulmonary thromboembolism particularly in cases involving the central pulmonary arteries or peripheral wedge shaped opacity as useful indirect sign.","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":"3 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78245932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA3126
L. Marconi, Valentina Foci, M. Lazzeretti, A. Palla
{"title":"Recurrence and bleeding in the extended treatment of patients with pulmonary embolism (PE) and cancer","authors":"L. Marconi, Valentina Foci, M. Lazzeretti, A. Palla","doi":"10.1183/13993003.CONGRESS-2018.PA3126","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3126","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":"156 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76796600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA3122
Jang Ho Lee, Jae Seung Lee
Introduction and Objectives: Although low-molecular-weight heparin (LMWH) remains the standard treatment for venous thromboembolism (VTE) in patients with active cancer, a factor Xa inhibitor such as rivaroxaban is increasingly used without clinical evidence. We compared the incidence of bleeding and other treatment outcomes using rivaroxaban and LMWH for the treatment of VTE in patients with gastrointestinal and pancreatobiliary cancer (GI cancer). Methods: This single-center retrospective analysis included patients with VTE associated with GI cancer, who were treated with either rivaroxaban or LMWH. The primary end-point was the incidence of clinically relevant bleeding. Secondary outcomes included the incidence of major bleeding, recurrent VTE, and mortality. Results: Of 281 patients, 78 received rivaroxaban and 203 received LMWH. Clinically relevant bleeding occurred in 20 patients (26%) in the rivaroxaban group and 31 (15%) in the LMWH group (P=0.043). There was no statistically significant difference in the VTE recurrence rate (4% with rivaroxaban vs. 4% with LMWH, P>0.999) or incidence of major bleeding (5% with rivaroxaban vs. 9% with LMWH, P=0.296). Multivariate Cox proportional hazards analysis for cancer type, stage, chemotherapy history, and Eastern Cooperative Oncology Group performance status showed a 1.904-fold higher risk of bleeding with rivaroxaban (1.031 to 3.516, P=0.040). Rivaroxaban use was not associated with a higher hazard ratio than LMWH use for all-cause mortality (HR 1.00, P=0.999). Conclusions: Rivaroxaban use was associated with more bleeding than LMWH use in GI cancer patients.
{"title":"Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer","authors":"Jang Ho Lee, Jae Seung Lee","doi":"10.1183/13993003.CONGRESS-2018.PA3122","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3122","url":null,"abstract":"Introduction and Objectives: Although low-molecular-weight heparin (LMWH) remains the standard treatment for venous thromboembolism (VTE) in patients with active cancer, a factor Xa inhibitor such as rivaroxaban is increasingly used without clinical evidence. We compared the incidence of bleeding and other treatment outcomes using rivaroxaban and LMWH for the treatment of VTE in patients with gastrointestinal and pancreatobiliary cancer (GI cancer). Methods: This single-center retrospective analysis included patients with VTE associated with GI cancer, who were treated with either rivaroxaban or LMWH. The primary end-point was the incidence of clinically relevant bleeding. Secondary outcomes included the incidence of major bleeding, recurrent VTE, and mortality. Results: Of 281 patients, 78 received rivaroxaban and 203 received LMWH. Clinically relevant bleeding occurred in 20 patients (26%) in the rivaroxaban group and 31 (15%) in the LMWH group (P=0.043). There was no statistically significant difference in the VTE recurrence rate (4% with rivaroxaban vs. 4% with LMWH, P>0.999) or incidence of major bleeding (5% with rivaroxaban vs. 9% with LMWH, P=0.296). Multivariate Cox proportional hazards analysis for cancer type, stage, chemotherapy history, and Eastern Cooperative Oncology Group performance status showed a 1.904-fold higher risk of bleeding with rivaroxaban (1.031 to 3.516, P=0.040). Rivaroxaban use was not associated with a higher hazard ratio than LMWH use for all-cause mortality (HR 1.00, P=0.999). Conclusions: Rivaroxaban use was associated with more bleeding than LMWH use in GI cancer patients.","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82054419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA3116
Rosen Petkov, N. Kurtelova, Y. Yamakova, E. Mekov
Clinical symptoms of pulmonary embolism (PE) are nonspecific and multidetector CT pulmonary angiography (MCTPA) is largely used as a second-line imaging test, exposing patients to high-dose radiation and potential complications. The aim of this study is to investigate the diagnostic value of multiorgan ultrasonography (MOUS): chest (ChUS), heart (EchCG), and leg vein compression ultrasonography (CUS) combined with Wells score and D-dimer. Methods: In a prospective study (02.2017-02.2018) we observed 55 consecutive adults (28 males and 27 females) age x = 56.2 ± SD 14.0 with suspected PE. All patients with Wells score >4 and those with score Results: PE was diagnosed in 42 of 55 enrolled patients (76.4%). ChUS yielded sensitivity (Se) 66% and specificity (Sp) of 77%, EchCG 69% and 92%, and CUS 59% and 100%, respectively. One positive result of MOUS was with accuracy (Acc) 91%, Se 95%, Sp 77% for PE. In patients with ≥2 positive US tests the Acc was 84%, Se 81% and Sp 92%. No patient received PE as a final diagnosis among the MOUS negative patients (n=10, 18%). Conclusions: MOUS is more accurate and sensitive than each one single-organ ultrasonography. In emergency conditions and/or in cases contraindicated for CTPA it could be used as an alternative imaging method for PE diagnosis, safely reducing the MCTPA burden.
{"title":"Multiorgan ultrasonography for the diagnosis of pulmonary embolism","authors":"Rosen Petkov, N. Kurtelova, Y. Yamakova, E. Mekov","doi":"10.1183/13993003.CONGRESS-2018.PA3116","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3116","url":null,"abstract":"Clinical symptoms of pulmonary embolism (PE) are nonspecific and multidetector CT pulmonary angiography (MCTPA) is largely used as a second-line imaging test, exposing patients to high-dose radiation and potential complications. The aim of this study is to investigate the diagnostic value of multiorgan ultrasonography (MOUS): chest (ChUS), heart (EchCG), and leg vein compression ultrasonography (CUS) combined with Wells score and D-dimer. Methods: In a prospective study (02.2017-02.2018) we observed 55 consecutive adults (28 males and 27 females) age x = 56.2 ± SD 14.0 with suspected PE. All patients with Wells score >4 and those with score Results: PE was diagnosed in 42 of 55 enrolled patients (76.4%). ChUS yielded sensitivity (Se) 66% and specificity (Sp) of 77%, EchCG 69% and 92%, and CUS 59% and 100%, respectively. One positive result of MOUS was with accuracy (Acc) 91%, Se 95%, Sp 77% for PE. In patients with ≥2 positive US tests the Acc was 84%, Se 81% and Sp 92%. No patient received PE as a final diagnosis among the MOUS negative patients (n=10, 18%). Conclusions: MOUS is more accurate and sensitive than each one single-organ ultrasonography. In emergency conditions and/or in cases contraindicated for CTPA it could be used as an alternative imaging method for PE diagnosis, safely reducing the MCTPA burden.","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":"36 6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82709544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.oa3600
I. Basyigit, S. Barış, Tuba Çiftçi, S. Ozgun, H. Boyacı
{"title":"The evaluation of medication adherence in patients with pulmonary thromboembolism","authors":"I. Basyigit, S. Barış, Tuba Çiftçi, S. Ozgun, H. Boyacı","doi":"10.1183/13993003.congress-2018.oa3600","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.oa3600","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91154511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.oa3597
S. Parsa, N. Hosseinvand, S. Peiman
{"title":"The prognostic value of Red cell distribution width(RDW) in acute pulmonary thromboembolism","authors":"S. Parsa, N. Hosseinvand, S. Peiman","doi":"10.1183/13993003.congress-2018.oa3597","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.oa3597","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":"365 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83027275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.oa3599
R. Pancani, L. Villari, F. Aquilini, A. Celi, A. Palla
{"title":"Prognostic role of respiratory failure in acute pulmonary embolism:a pulmonologist’s point of view","authors":"R. Pancani, L. Villari, F. Aquilini, A. Celi, A. Palla","doi":"10.1183/13993003.congress-2018.oa3599","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.oa3599","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90999702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.OA3593
L. Moth, L. Mcdonnell, L. Osman, P. Marino, G. Arbane, George Kaltsakas, B. Mukherjee
{"title":"Late Breaking Abstract - An evaluation of standard UK pulmonary rehabilitation post pulmonary embolism","authors":"L. Moth, L. Mcdonnell, L. Osman, P. Marino, G. Arbane, George Kaltsakas, B. Mukherjee","doi":"10.1183/13993003.CONGRESS-2018.OA3593","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.OA3593","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86123114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：